Evidence map›Paper›PMID 24422669›Full record

ArticleRetrovirology2014

HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3.

Sean L Evans, Arne Schön, Qimeng Gao, Xue Han, Xiaohong Zhou, Ernesto Freire, Xiao-Fang Yu

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.Protein science : a publication of the Protein Society · 2020
    Review
  6. Article
  7. Review
  8. Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource.Database : the journal of biological databases and curation · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sean L Evans
Arne Schön
Qimeng Gao
Xue Han
Xiaohong Zhou
Ernesto Freire
Xiao-Fang YuDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N, Wolfe Street, Baltimore, MD 21205, USA. xfyu@jhsph.edu.
Johns Hopkins University · USJilin University · CN

Funding

Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2M
STRUCTURE BASED THERMODYNAMIC STUDIES OF HIV1 PROTEASER01GM057144 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FREIRE, ERNESTO · 1998 to 2012
$5.8M
Identification of novel anti-HIV inhibitors based on Vif-E3 activityR21AI102798 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARKHAM, RICHARD B. · 2013 to 2014
$431k
Interaction between HIV-1 Vif and a Host Key Immune Regulator ComponentF31AI091326 · NIAID · JOHNS HOPKINS UNIVERSITY · PI EVANS, SEAN LAMONTE · 2011 to 2012
$84k
NIAID NIH HHS AI102798NIAID NIH HHS F31 AI091326NIAID NIH HHS R21 AI102798NIGMS NIH HHS GM56550NIGMS NIH HHS GM57144
6 · The paper itself

Abstract

backgroundHIV-1 Vif promotes the degradation of host anti-retroviral factor family, APOBEC3 proteins via the recruitment of a multi-subunit E3 ubiquitin ligase complex. The complex is composed of a scaffold protein, Cullin 5 (Cul5), RING-box protein (Rbx), a SOCS box binding protein complex, Elongins B/C (Elo B/C), as well as newly identified host co-factor, core binding factor beta (CBF-β). Cul5 has previously been shown to bind amino acids within an HCCH domain as well as a PPLP motif at the C-terminus of Vif; however, it is unclear whether Cul5 binding requires additional regions of the Vif polypeptide.

resultsHere, we provide evidence that an amino terminal region of full length Vif is necessary for the Vif-Cul5 interaction. Single alanine replacement of select amino acids spanning residues 25-30 (25VXHXMY30) reduced the ability for Vif to bind Cul5, but not CBF-β or Elo B/C in pull-down experiments. In addition, recombinant Vif mutants had a reduced binding affinity for Cul5 compared to wild-type as measured by isothermal titration calorimetry. N-terminal mutants that demonstrated reduced Cul5 binding were also unable to degrade APOBEC3G as well as APOBEC3F and were unable to restore HIV infectivity, in the presence of APOBEC3G. Although the Vif N-terminal amino acids were necessary for Cul5 interaction, the mutation of each residue to alanine induced a change in the secondary structure of the Vif-CBF-β-Elo B/C complex as suggested by results from circular dichroism spectroscopy and size-exclusion chromatography experiments. Surprisingly, the replacement of His108 to alanine also contributed to the Vif structure. Thus, it is unclear whether the amino acids contribute to a direct interaction with Cul5 or whether the amino acids are responsible for the structural organization of the Vif protein that promotes Cul5 binding.

conclusionsTaken together, we propose a novel Vif N-terminal motif that is responsible for Vif recruitment of Cul5. Motifs in Vif that are absent from cellular proteins represent attractive targets for future HIV pharmaceutical design.

Indexed as

Immune EvasionAPOBEC-3G DeaminaseCullin ProteinsCytidine DeaminaseCytosine DeaminaseHIV-1HumansProtein Interaction MappingProteolysisvif Gene Products, Human Immunodeficiency VirusAPOBEC3F protein, humanAPOBEC-3G DeaminaseAPOBEC3G protein, humanCUL5 protein, humanCullin ProteinsCytidine DeaminaseCytosine Deaminasevif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1

Identifiers

PMID24422669
PMCPMC3937519
OpenAlexW2115726308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.